Drug intelligence / Profile preview

VCC-003

Development stage: Preclinical
Lead developer: Vaccentis
Modality: Vaccines & Immunotherapeutics

Overview

VCC-003 is a therapeutic cancer vaccine currently in preclinical development by Vaccentis for the treatment of colorectal cancer. The vaccine is developed using the company's All Individualized Precision Immunotherapy (AIPI) technology platform, which creates autologous tumor vaccines tailored to the unique antigen profile of each patient's tumor. By presenting these individual tumor-specific antigens to the immune system, VCC-003 aims to stimulate a targeted immune response to recognize and eliminate colorectal cancer cells.

Targets

pMHC-I (Peptide–MHC class I complex)pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on VCC-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCC-003.